Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 6/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20114232 | 0.85 | NUDT1 (0.55) | NUDT1HRH4KCNH2HRH3 | |
| SCHEMBL18019806 | 0.85 | NUDT1 (0.55) | NUDT1HRH4KCNH2HRH3 | |
| SCHEMBL18019876 | 0.85 | NUDT1 (0.55) | NUDT1HRH4KCNH2HRH3 | |
| SCHEMBL17979752 | 0.85 | NUDT1 (0.55) | NUDT1HRH4KCNH2HRH3 | |
| SCHEMBL18019761 | 0.83 | NUDT1 (0.52) | NUDT1 | |
| SCHEMBL18019760 | 0.83 | NUDT1 (0.52) | NUDT1HRH4KCNH2HRH3 | |
| SCHEMBL18019759 | 0.83 | NUDT1 (0.52) | NUDT1 | |
| SCHEMBL17979799 | 0.81 | NUDT1 (0.56) | NUDT1HRH4KCNH2HRH3 | |
| SCHEMBL28174091 | 0.81 | NUDT1 (0.50) | NUDT1 | |
| SCHEMBL18019758 | 0.78 | NUDT1 (0.47) | NUDT1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | claimed |
| EP-3256132-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-12-20 | — | — | EP | claimed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | claimed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| EP-3256132-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | NUDT1 10/4885HRH4 2404/4885EGLN2 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.